Allarity Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 8, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. PROPERTIES
Our principal executive office is in Boston, MA USA, where we lease at-will, month-to-month virtual office space in a technology park, where we are not bound by any lease. Our current monthly rent for the office space is approximately $85 per month. We believe this office is sufficient to support our U.S.-based executive team members, all of whom are based on the East Coast of the U.S. In each of the fiscal years ended December 31, 2023 and 2022, we paid approximately $1,110 in lease payments. We believe that our current existing facilities will be adequate for our current needs.
Our principal laboratory and R&D facility is in Hoersholm, Denmark (just north of Copenhagen), where we lease a space in a technology park consisting of approximately 4,283 square feet, for $8,107 per month. As of January 31, 2023, the facility lease is continuing on a month-to-month basis. In each of the fiscal years ended December 31, 2023 and 2022, we paid approximately $97,284 in lease payments.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.